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The discovery of follicular B helper T (TFH) cells has its roots in the early 90s, the “childhood” of
chemokine research that has since grown into an independent, global specialty within immunology.
The class of chemoattractant proteins with shared structural features was named “chemokines,” and
early work with non-chemokine (FMLP, C5a) and chemokine (IL-8/CXCL8) receptors revealed
that chemokine receptors belong to the large family of G-protein-coupled receptors (GPCRs)
distinguished by their prototypical seven-transmembrane protein architecture. The search for novel
chemokines and their receptors greatly intensified during that time, because it became increasingly
clear that this novel cytokine system is essential for controlling immune cell mobilization and
tissue localization and, hence, for controlling the entirety of immune processes in health and
disease. Molecular identification of chemokine receptors led to the identification of immune cells
that responded to the corresponding chemokine ligands and allowed their tracking during acute
and chronic immune responses. At the last count, the inventory of chemokine receptors that,
together with adhesion receptors, make up the address codes on human immune cells includes 18
individual members recognizing one or multiple of a total of 45 chemokines. Further underscoring
the complexity of the chemokine system, we also know of six atypical chemokine receptors, some of
which control chemokine positioning and degradation.
Sincemy earliest steps in research, I was fascinated by the cytokine network controlling the highly
complex interactions between immune cells and their functions in immune defense. In fact, an
ambitious project aimed at the molecular characterization of the elusive “antigen-specific T helper
factors” tipped the balance in favor of carrying outmy Ph.D. studies in the lab of Profs. D. G. Kilburn,
R. C. Miller Jr., and R. A. J. Warren at the University of British Columbia in Vancouver. It was not
the skiing in the Whistler Mountains nor the salmon fishing along the Sunshine Coast that did the
job, as suggested by some of my colleagues at the Federal Institute of Technology in Zurich. Needless
to say that the molecular identification of the T cell antigen receptor in 1984 brought our project to
an immediate halt. Still, when the question about postdoc projects arose, I was fascinated by the new
world of chemotactic cytokines (to be called “chemokines” a few years later) that I was introduced
to by Prof. Marco Baggiolini, the director at the Theodor-Kocher Institute of the University of
Bern. Therefore, upon arrival at the Theodor-Kocher Institute in 1989, I was determined to clone
the receptor for NAF, the first chemokine with selectivity for neutrophils (now known as IL-8 or
CXCL8 according to the systematic chemokine nomenclature). This young field of research turned
out to be highly competitive, not least because of its translational potential. Unsurprisingly, we were
beaten by two labs who reported the cloning of the CXCL8 receptors well before our own initiative
had a chance to take off (1, 2). As a small consolation, we succeeded to be first in demonstrating
that human neutrophils carried two types of CXCL8 receptors on their cell surface distinguished
by their variable affinity for other CXCL8-related chemokines (3, 4). Still, our multipronged
cloning efforts paid off and revealed numerous orphan GPCRs with similarity to the CXCL8
receptors. In a great team effort by many colleagues, including Marcel Loetscher, Daniel Legler,
Patrick Schaerli, and Regula Stuber-Roos, together with the protein chemist Ian Clark-Lewis at the
Biomedical Research Centre of the University of British Columbia (who sadly died in 2002), we were
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FIGURE 1 | Follicular B helper T (TFH) cells. T cells reach the lymph node
paracortical region (T zone) via high endothelial venules (blood) or afferent
lymphatics (peripheral tissues) in response to the CCR7-specific chemokines
CCL19 and CCL21. During contact with antigen-presenting DC, T cells become
primed that includes induction of CXCR5 expression. Reduced CCR7
expression allows newly generated CXCR5+ T (TFH) cells to respond to follicular
CXCL13 and to relocate to the B cell follicles where TFH-B cell interactions
involving a series of co-stimulatory receptors (CD40, ICOS, etc.) and cytokines
(IL-10, IL-21, etc.) initiate the germinal center reaction and the formation of
antibody-secreting plasma cells and memory B cells. TNaive, naïve T cells; TCM,
central memory T cells; TFH, follicular B helper T cells; B, B cells; BEffector,
plasma cells; BMemory, memory B cells.
then able to “deorphanize” some of these novel GPCRs in the
subsequent years.
As part of our chemokine receptor cloning initiatives, Luca
Barella, who was a Ph.D. student in my lab, identified and char-
acterized an orphan GPCR, termed monocyte-derived receptor
15 (MDR15) (5), which turned out to be a structural variant of
Burkitt’s lymphoma receptor 1 (BLR1) published several years
ahead of us by Martin Lipp’s group in Berlin (6). In fact, we
first heard about BLR1 during a conversation with Martin Lipp
whom we met in July 1992 at the fifth International Congress on
Cell Biology in Madrid. Based on the structural similarities to
the chemokine receptors that were known at that time (CXCR1,
CXCR2, CCR1, and CCR2), it was clear to us that MDR15/BLR1
must be a novel chemokine receptor. However, none of the known
chemokines bound to it.
Intriguingly, MDR15/BLR1 transcripts were primarily found
to be present in the lymphocyte fraction of peripheral blood
mononuclear cells, and most notably in chronic B leukemia
cell lines, but not in cells characterized by the other known
chemokine receptors. It took another 3 years to “deorphanize”
MDR15/BLR1. While searching expressed sequence tag (EST)
cDNA databanks, Daniel Legler, a Ph.D. student at that time,
identified a novel chemokine, which we termed B cell-attracting
chemokine 1 (BCA-1; now officially known as CXCL13) because
of its efficacious chemoattractant activity for B cells (7). The
mouse ortholog of BCA-1/CXCL13 was published by the group
of Michael Gunn at UCSF within the same month (8). Impor-
tantly, Michael Gunn and our group found that BCA-1/CXCL13
was the selective chemokine ligand for mouse and human
MDR15/BLR1 (now officially known as CXCR5), respectively.
Of note, the highly selective expression of CXCL13 in sec-
ondary lymphoid tissues matched perfectly well the findings
of Martin Lipp’s group about the importance of BLR1 in
the localization of B cells within murine secondary lymphoid
tissues (9).
In addition to B cells, we noticed that a large fraction of
CD4+ memory T cells present in tonsils expressed CXCR5. By
contrast, CXCR5+ T cells were relatively scarce in peripheral
blood of healthy individuals. We also found that its single lig-
and CXCL13 was discretely expressed in the follicular mantle
zone but not in the paracortical T cell zone or high endothelial
venules where the CCR7-specific chemokines CCL19 and CCL21
are present. Unlike CCL19/CCL21, it appeared that CXCL13
did not play a role in the recruitment of T cells (and B cells)
into lymph nodes but instead controlled the segregation of lym-
phocytes between T cell and B cell compartments, as Michael
Gunn’s group has shown for BLC in mice (10). Could it be
that tonsillar CXCR5+ T cells corresponded to the elusive T
helper cell subset postulated to control B cell responses to protein
antigens? Indeed, tonsillar B cells produced large amounts of
isotype-switched antibodies during co-culture with CXCR5+ T
cells but not CXCR5- T cells. During a subsequent discussion
with Martin Lipp, who contributed his CCR7-specific antibodies
to our study, we found out that both of our groups had simi-
lar results and, therefore, we agreed to submit our findings as
back-to-backmanuscripts to the Journal of ExperimentalMedicine
(11, 12). Together with the journal editors, we then decided to
designate this novel T helper subset as TFH cells, which today
is also known as “follicular helper T cells” and “B helper T
cells” (Figure 1).
The separation of T helper cells into Th1 and Th2 cells was
instrumental in delineating immune responses to distinct classes
of pathogens, such as viruses and intracellular bacteria for Th1
cells and extracellular pathogens and allergens for Th2 cells.
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Following the fundamental dogma underscoring the insepa-
rable relationship between tissue localization and immune cell
function, we and Martin Lipp’s group jointly discovered TFH cells
as a third distinct T helper cell subset, which was highlighted in
a commentary by Charles Mackay (13). An avalanche of murine
studies by numerous outstanding labs worldwide confirmed and
extended our initial findings about the role played by TFH cells
in humoral immunity. Thanks to their efforts, it is now clear that
defects in their generation and/or function have a profound effect
on antibody dependent immune responses. In fact, increased
numbers of TFH cells are now known to be associated with B cell
autoimmunity and lymphomas whereas defects in TFH cell gener-
ation cause severe humoral immunodeficiency [reviewed in Ref.
(14)]. Finally, since the presence of CXCR5+ T cells in peripheral
blood reflects ongoing humoral immune responses (15), CXCR5
may even serve as a unique and convenient biomarker for the eval-
uation of ongoing vaccination responses. Today, TFH cells have a
firm place among an increasing number of T helper cell subsets
distinguished by their characteristic migration and functional
properties.
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